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Abstract
Background: The World Health Assembly has adopted a global strategy to eliminate cervical cancer. However,
neither the optimal pathway nor the corresponding economic and health benefits have been evaluated. We take
China as an example to assess the optimal pathway towards elimination and the cost-effectiveness of tailored
actions.
Methods: A validated hybrid model was used to assess the costs and benefits of alternative strategies combining
human papillomavirus vaccination, cervical screening, and treatment of pre-invasive lesions and invasive cancer for
females with different immunization history. All Chinese females living or projected to be born during 2015–2100,
under projected trends in aging, urbanization, and sexual activity, were considered. Optimal strategies were
determined by cost-effectiveness efficiency frontiers. Primary outcomes were cervical cancer cases and deaths
averted and incremental cost-effectiveness ratios (ICERs). We employed a lifetime horizon from a societal
perspective. One-way and probabilistic sensitivity analyses evaluate model uncertainty.
Results: The optimal pathway represents an integration of multiple tailored strategies from females with different
immunization history. If China adopts the optimal pathway, the age-standardized incidence of cervical cancer is
predicted to decrease to fewer than four new cases per 100,000 women (i.e., elimination) by 2047 (95% confidence
interval 2043 to 2050). Compared to the status quo, the optimal pathway would avert a total of 7,509,192 (6,922,744
to 8,359,074) cervical cancer cases and 2,529,873 (2,366,826 to 2,802,604) cervical cancer deaths in 2021–2100, with
the discounted ICER being $− 339 (− 687 to − 79) per quality-adjusted life-year.
Conclusions: By adopting an optimal pathway from 2021 (namely, the year of the first Chinese Centennial Goals)
onwards, cervical cancer could be eliminated by the late 2040s (namely, ahead of the second Chinese Centennial
Goals) while saving net economic costs in China.
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Background
Following the call from the World Health Organization
(WHO)’s Director-General for action towards the elimin-
ation of cervical cancer as a public health problem, several
modeling studies suggested that the goal of elimination is
within reach globally in the twenty-first century [1–3]. All
of these studies were designed to evaluate the time frame
and intervention strategies needed to achieve cervical can-
cer elimination or to predict the impact on cervical cancer
mortality and deaths averted [1–3]. In August 2020, the
World Health Assembly has adopted the global strategy to
accelerate the elimination of cervical cancer. However, to
the best of our knowledge, a full economic evaluation of a
comprehensive cervical cancer elimination strategy has yet
to be performed.
China contributed to 20.2% of the global burden of cer-
vical cancer, and the incidence showed a significant rise of
up to 10.5% per year [4]. The mean age of cervical cancer
patients was about 53 years, and 57.6% of patients were di-
agnosed as stage I [4, 5]. HPV prevalence in cervical can-
cer patients was 97.6% in China, with HPV-16 and HPV-
18 accounting for 59.5 and 9.6%, respectively [6]. How-
ever, China has not yet included human papillomavirus
(HPV) vaccination into its national immunization pro-
gram (NIP), and the 3-year coverage rate of cervical
screening in women aged 35–64 years was 22.6% [7, 8]. At
the end of 2019, China’s first domestically produced bi-
valent HPV vaccine (Cecolin™) was approved for cervical
cancer prevention in the female population aged 9–45
years [9]. The 5.5-year follow-up suggested that the vac-
cine is highly efficacious in preventing genital lesions and
persistent infection associated with HPV-16/18, with no
waning protection detected after vaccination [10, 11]. In
2020, the issue of introducing HPV vaccination into the
NIP was submitted to the Chinese government for consid-
eration [12]. In the absence of evidence-based analyses on
the impact of an optimal strategy involving both HPV vac-
cination and cervical cancer screening, policy-makers in
China are still hesitant to make major changes.
Although there is great optimism about eliminating cer-
vical cancer in China [13], the optimal pathway considering
the availability of healthcare resources and health equity
has not been established. Therefore, from the perspective of
public health investment, a full health economic evaluation
needs to be carried out. Our present study assesses the op-
timal pathway towards cervical cancer elimination in the
twenty-first century in China, evaluates the economic in-
vestment needed to adopt the proposed activities, and dis-
cusses its significance for public health.
Methods
The results were reported following the Consolidated
Health Economic Evaluation Reporting Standards State-
ment (CHEERS) (Additional file 1: CHEERS checklist).
In this model-based economic evaluation, we assessed
the effect of several HPV vaccination and cervical
screening scenarios on cervical cancer elimination in
China under projected aging, urbanization, and sexual
activity trends. All Chinese women living or projected to
be born during 2015–2100 were considered to obtain es-
timates of costs and health outcomes of all strategies.
The population was stratified by area of residence (urban
and rural), gender, sexual activity (high, low, none), and
age group (0–84 per year, and 85+).
Mathematical model
We updated the hybrid model which was developed to
evaluate cervical cancer prevention strategies in China
[14]. Please see Additional file 2 for more details on the
model (Additional file 2: Table S1–S6 and Figure S1–S2)
[2, 3, 6, 7, 9, 11, 12, 14–49]. We incorporated 13 HPV
strains into our analyses and modeled the impact of
every high-risk HPV strain separately [50]. The number
of women in each disease state, year, risk group, HPV
type (if infected), and age estimated from a dynamic
transmission model was fed into the natural history
model to simulate the costs and outcomes of each
strategy.
Models were calibrated using epidemiological data of
high-risk HPV prevalence, cervical incidence and mor-
tality in 2015, HPV type distributions in women with
normal cervical cytology, low-grade cervical precancer-
ous lesions, high-grade cervical precancerous lesions,
and invasive cervical cancer (Additional file 2: Table S3–
S6 and Figure S2) [6, 47–49, 51].
Inputs and assumptions
Base-case estimates and ranges for all parameters are
listed in tables in the supplementary file (Additional file 2:
Table S2) [2, 3, 14, 19, 26, 28, 30–45]. We assumed that
infection-acquired immunity would wane over time,
whereas vaccine-acquired immunity would be lifelong
[2, 3, 40, 52]. For the base-case analyses, HPV vaccin-
ation was assumed to provide full efficacy against
vaccine-targeted HPV types, while the cross-protection
against non-vaccine targeted types was not considered.
The screening algorithm selected for modeling involved
primary screening with the high-risk HPV test and triag-
ing of the HPV-positive women with liquid-based cy-
tology (LBC). The sensitivity of HPV DNA testing was
assumed to be 90% for cervical intraepithelial neoplasia
(CIN) grade 2, 94% for CIN3, and 100% for invasive cer-
vical cancer. Age-specific cervical cancer survival rates
were extracted from population-based cancer registries
in urban and rural China [53].
We derived utility values that were specific for pa-
tients’ health and treatment state from our hospital-
based prospective study in China [44]. Health-related
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quality of life for patients undergoing treatment for
CIN1 and those receiving terminal care was based on
internationally published data [43].
Costs of domestically manufactured bivalent HPV vac-
cine and 9-valent HPV vaccine in the NIP were assumed
to be $4.6 and $6.6 per dose, respectively, and the vac-
cine administration cost was estimated at $3.83 per dose
(Additional file 2: Table S2) [7, 9, 11, 12, 15–20]. Cer-
vical screening costs using LBC and HPV DNA testing
were estimated at $9.46 and $15.13 per screen in urban
areas, and $7.00 and $12.98 per screen in rural areas, re-
spectively (Additional file 2: Table S1) [6, 21–27, 29].
We considered all components of direct medical cost,
direct non-medical costs, and indirect costs for women
diagnosed with CIN and invasive cervical cancer. All
unit costs were adjusted to the year 2020 using the
government-reported consumer price index for health
care [51] and then converted into US dollar using ex-
change rates for early 2020 (i.e., 1.00 US dollar = 7.00
Chinese yuan).
Alternative scenarios
Considering the progress of HPV vaccine research and
development in China, the domestically manufactured
bivalent HPV vaccine is the only product that will be
considered for inclusion in the NIP until 2030; after that
year, domestically manufactured low-cost 9-valent HPV
vaccine will also be considered [54]. HPV vaccination is
assumed to be delivered to girls aged 9 years with two
dose regimens routinely and catch-up to 14 years (two
dose regimens) or to 25 years (three dose regimens for
girls aged 15 and older) [10]. HPV-based cervical screen-
ing is assumed to be targeted at women aged 35–64
years. We considered six alternative screening strategies
for unvaccinated women and 23 alternative strategies for
vaccinated women (Additional file 2: Figure S3). Cur-
rently, about 45% of women diagnosed with CIN1 are
treated in China (Additional file 2: Table S2) [14]. We
assume that the practice will change from 2031, with
women with CIN1 undergoing two follow-up visits be-
fore being treated.
We assumed the maximum achievable coverage of
routine vaccination and catch-up vaccination would be
95% and 90%, respectively, and that maximum achiev-
able coverage of cervical screening would be 90% [14].
Due to shortages in HPV vaccine supply [55], we assume
that China will vaccinate only 9-year-old girls in 2021,
and catch-up vaccination would be scaled-up to girls/
women aged 10–14 or 10–25 years in 2022–2025. The
maximum capacity for cervical screening in China in
2021 is estimated to be 35 million women [8, 56]; there-
fore, if China screens women aged 35–64 every 3 years,
the maximum achievable coverage would be 35% in
2021, while if China shifts the screening interval to 5
years, the maximum achievable coverage would be 60%
in 2021. We assumed that screening coverage would
scale up by 5% every year until it reaches 70%, following
which the rate of increase would slow down to 3% every
year till 90% coverage is achieved.
Outcomes
We estimated the lifetime costs and health benefits for
each strategy in comparison with the status quo strategy
(3-yearly screening with coverage of 26.6% in urban
areas and 19.3% in rural areas; HPV vaccination cover-
age is negligible) in China [14]. The cost of implement-
ing each strategy was estimated from a societal
perspective. The health outcomes of each strategy were
evaluated in quality-adjusted life-years (QALYs), taking
into account health state utility weights. Both costs and
health outcomes were discounted at an annual rate of
3% [45].
In the base-case analysis, status quo strategy and opti-
mal strategy were evaluated in the model to estimate the
year of cervical cancer elimination, averted cervical can-
cer cases and deaths, and the incremental cost-
effectiveness ratios (ICER) for urban and rural areas, re-
spectively. The ICER was calculated as incremental cost
per additional QALY gained between optimal strategy
and status quo.
We calculated age-standardized annual incidence and
mortality rates using Segi’s world standard population.
Elimination of cervical cancer as a public health problem
was defined as the first year when the age-standardized
incidence is below 4/100,000 women.
Main analysis
Using the calibrated model, we assessed the costs and
benefits of all alternative scenarios in birth cohorts with
different HPV immunization history (unvaccinated, vac-
cinated with a bivalent vaccine, and vaccinated with a 9-
valent vaccine), different target ages at vaccination and
coverage, and different cervical screening characteristics
(with different target ages, screening intervals, and
coverage). A five-stage analytic process was involved to
determine the optimal pathway (Additional file 2: Table
S7–S8 and Figure S3). We selected the optimal strategies
by determining the ICER as compared with the next-
least-expensive strategy lying on the efficiency frontier
(next-best strategy). We applied the Chinese median an-
nual income ($3789) and gross domestic product (GDP)
per capita ($10,276) as the threshold ICER when select-
ing the optimal strategies [57, 58].
Sensitivity analysis
We varied each input value in the model over a plausible
range in one-way deterministic sensitivity analyses to
examine the impact of uncertainty in individual input
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parameters on the results. Probabilistic sensitivity ana-
lysis was conducted by performing 1000 Monte Carlo
simulations to sample parameter values from their distri-
butions and estimate outcomes. The results of the prob-
abilistic sensitivity analysis were used to calculate the
95% confidence intervals (CIs) of model results.
Results
The optimal pathway towards the elimination of cervical
cancer in China is to integrate the tailored optimal strat-
egies of different birth cohorts under the constraints of
available resources (Fig. 1 and Additional file 2: Table
S7–8 and Figure S3). Specifically, routine bivalent HPV
vaccination should be initiated in 2021 for girls (at 95%
expected coverage) aged 9 years old and switched to 9-
valent vaccine in 2031 when it becomes available for the
Chinese NIP. Catch-up vaccination should target girls
(at 90% expected coverage) up to 25 years old in 2022–
2025, with the most rapid scale-up possible under the
expected vaccine supply constraints. HPV-based screen-
ing should be offered (at 90% expected coverage) to un-
vaccinated women aged 35–64 every 5 years, with the
most rapid scale-up to the population possible under the
constraints of screening service resources. For the bi-
valent vaccinated cohort, screening should target women
aged 40–55 every 5 years, while for the 9-valent vacci-
nated cohort, screening at 40, 45, and 55 would be a
cost-effective strategy while gaining the most benefits.
The optimal pathway is predicted to lead to cervical
cancer elimination in China by 2047 (95% CI, 2043 to
2050) (Fig. 2). This pathway is a cost-saving strategy
with a discounted ICER of $− 339 (− 687 to − 79) per
QALY compared to the status quo strategy (Table 1). A
total of 7,509,192 (6,922,744 to 8,359,074) cervical can-
cer cases and 2,529,873 (2,366,826 to 2,802,604) cervical
cancer deaths in 2021–2100 would further be averted in
China by adopting the optimal pathway compared to the
status quo (Table 2). Cervical cancer elimination can be
achieved by 2046 (2041 to 2050) in urban areas and
2050 (2045 to 2053) in rural areas, with the discounted
ICER being $− 511 (− 913 to − 199) per QALY in urban
areas and $234 (− 120 to 544) per QALY in rural areas
compared to the status quo strategy. We estimated that
the optimal pathway would further averts 5,714,707
Fig. 1 Optimal pathway towards cervical cancer elimination. The percentages and background colors in each cell indicate the population
coverages. HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia
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(5,227,933 to 6,387,465) and 1,794,485 (1,538,873 to
2,131,125) cervical cancer cases, and 1,939,440 (1,796,
327 to 2,161,390) and 590,432 (507,330 to 702,435)
cervical cancer deaths compared to the status quo in
urban areas and rural areas, respectively.
Net costs would be positive in 2021–2035 by adopting
the optimal pathway, while from 2036 onwards, annual
net costs would be negative, due to reductions in the
cost of invasive cervical cancer treatment (Fig. 3 and
Additional file 2: Figure S6–S7). Annual benefits (i.e., in-
cremental QALYs) of the optimal pathway would be
slightly lower than that of the status quo before 2026 be-
cause of the lead time from cervical screening, while it
would be much higher from 2027 onwards (Add-
itional file 2: Figure S8). More intensive screening strat-
egies would be considered cost-effective when using the
GDP per capita as the threshold (Additional file 2: Fig-
ure S9). The year of cervical cancer elimination would
thus be 11 years ahead of that using median income as
the threshold (Additional file 2: Figure S10). However,
the ICER would be $4344 (3357 to 6056) per QALY for
the optimal pathway using GDP per capita as the thresh-
old compared to the optimal pathway using the median
income as the threshold (Additional file 2: Table S9–S11
and Figure S11–S12).
The uncertainty ranges of individual variables had a
small-to-moderate effect on cost-effectiveness (ICER
range, $− 861 to $474 per QALY) (Additional file 2: Fig-
ure S4–S5). The model was most sensitive to the dis-
count rate, the clearance rate of HPV infection,
screening cost, transition probability, and cross-protect
of the bivalent vaccine. Input to which the results were
most sensitive was discount rate both in urban and rural
areas, which potentially increased the ICER to $219 per
QALY in urban areas and $1372 per QALY in rural
areas.
Discussion
We have conducted, for the first time, a health economic
evaluation to determine the optimal pathway and assess
the costs and benefits of strategies for cervical cancer
elimination worldwide. We estimated that cervical can-
cer could be eliminated as a public health problem by
the late 2040s in a cost-saving manner by adopting the
optimal pathway. Compared to the status quo, the opti-
mal pathway represents a saving of about $100 billion of
costs and 116 million of QALYs in women living or pro-
jected to born during 2021–2100 and averts about 7.5
million cervical cancer cases and 2.5 million cervical
cancer deaths in 2021–2100 in China.
Fig. 2 Age-standardized cervical cancer incidence and mortality for the optimal pathway. The solid line represents the base case estimates, and
the shaded area represents the 95% confidence intervals based on 1000 simulations of probabilistic sensitivity analysis
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Our previous study has quantified the impact of intro-
ducing bivalent HPV vaccine into the NIP on cervical
cancer elimination in China but did not provide eco-
nomic evidence [14]. In this study, we have addressed
the major limitations of our previous study by outlining
the optimal cervical cancer control pathway from the
perspective of cost-effectiveness [13, 14]. This study
builds on our previous work in several ways. First, we
used an age-structured population rather than a single
cohort to select the optimal strategies [13]. Second, we
considered all components of costs and employed
QALYs as the primary outcome, rather than only con-
sidered costs from the government and used the year of
elimination as the primary outcome. As a straightfor-
ward health economic evaluation, QALYs adopted in
this study are more adequate to quantify the optimal
strategy of cervical cancer elimination, because the earli-
est time of elimination is not necessarily those of highly
cost-effective. As such, findings in this study were more
informative and convincing to policy marker. Our previ-
ous study found that by reallocating part of the budget
earmarked for cervical cancer screening to HPV vaccin-
ation, China could achieve the goal of cervical cancer
elimination by the early 2070s without any increase in
total financial outlay [14]. However, if these strategies
are implemented under a fixed healthcare budget, this
may lead to worsened health inequities because it will
result in displacement in healthcare spending that may
benefit other people (e.g., reducing the budget originally
earmarked for screening in order to support the
Fig. 3 Annual costs from each component of cervical cancer prevention and treatment. Total costs and cost components for scenarios of the
optimal pathway (a) and status quo (b)
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inclusion of HPV vaccination in NIP, because vaccin-
ation is more cost-effective under a fixed budget con-
straint) [13, 14]. In this study, we synchronously
considered outcomes in urban and rural areas to select
the best strategy for the entire population with different
vaccination characteristics. Hence, the initial financial
outlay for the recommended pathway should ideally be
obtained through new funds. Lastly, the recommended
strategies represented by the optimal pathway in this
study change over time as population characteristics and
availability of technology advance. For example, we con-
sidered strategies as supply of vaccines and screening
services increased, and the possibility of switching to the
9-valent vaccine. All of those make the pathway pro-
vided by this study more realistic and feasible than an
evaluation conducted using static assumptions.
Taking considerations of the price and supply of HPV
vaccine and the preference of Chinese authorities, China
would likely introduce domestically manufactured HPV
vaccines into the NIP [7, 12, 15]. Nonetheless, the
current commercial price for domestic vaccines is still
too high for the NIP, so the healthcare sector has the re-
sponsibility of negotiating a competitive price with man-
ufacturers [17, 19]. Although the production capacity for
domestic vaccines is 30 million doses per year according
to the manufacturer [55], there is still insufficient vac-
cine supply to fulfill the peak demand under the optimal
strategy at 2024–2025. Therefore, increases in capacity
by domestic vaccine manufacturers are needed to sup-
port projected demand in the next 3 years [18]. On the
screening side, while more than 100 HPV testing tech-
nologies have been approved by the National Medical
Products Administration for cervical screening in China,
many of these lack necessary quality tracking and clinical
validation when introduced to the screening program
implemented by subnational governments. As such, it is
necessary to establish transparent tendering processes
for selecting and procurement of HPV tests, and establish
corresponding monitoring and management mechanisms
to ensure the quality of mass screening services. The na-
tional government can negotiate special prices for the
HPV detection tests to be used in the screening program,
thus making elimination more cost-effective. Furthermore,
measures should be taken to improve the adequate avail-
ability of effective coverage of cervical cancer treatment
modalities, especially in the rural areas [59].
Detailed country-level analyses, taking into account
specific local factors important for the effective delivery
of vaccination and screening interventions, will be key to
maximize the use of scarce resources to accelerate ef-
forts to eliminate cervical cancer, and should be viewed
as an important complement to global and regional ana-
lyses [3]. The speed of cervical cancer elimination in
China not only determines the progress of the Western
Pacific Region, but also substantially affects the global
strategy of eliminating cervical cancer as a public health
problem. Our research illustrates how China can develop
an optimal pathway towards cervical cancer elimination.
It can also serve as an example for other countries, espe-
cially those countries that have similar epidemiological
features and access to similar types of HPV-related
products as China, such as the WHO prequalified car-
eHPV™ test and Cecolin™ vaccine (under WHO prequali-
fication review) [11].
Our study has three major strengths. First, we
employed health economic evaluation to assess the costs
and benefits of the different strategies for cervical cancer
elimination, which makes a strong case for investment
by the policymakers in this area. Second, we have devel-
oped optimal strategies for a different population from
the perspective of health economic evaluation, which
makes it possible for China to achieve the goal of cer-
vical cancer elimination while saving net economic costs.
This approach highlights the importance of developing
the pathway to elimination rather than simply examining
the timeframe to achieve elimination. Third, we have
fully considered the accessibility of healthcare resources
and preferences of policy marking in China when we de-
velop the strategies. As such, the optimal pathway in our
study is more likely to be adopted by policy-makers and
then applied to the population.
Our study has three major limitations. First, we did
not consider the scenario of vaccination for boys and the
benefits gained from preventing other HPV infection-
related diseases. If the only goal is cervical cancer pre-
vention and elimination, then vaccination for boys is an
indirect and less cost-effective means of reaching this
goal [60]. We did not incorporate other disease out-
comes beyond cervical cancer because our estimates
suggest that HPV vaccination integrated into the optimal
pathway is already very cost-effective, and population
coverage is worth maximizing as soon as possible. Sec-
ond, the time horizon of our modeling extends to 2100,
but future outcomes may be subject to many unforesee-
able events that may occur before that. We have as-
sumed a very high coverage for both vaccination and
screening. While many countries have achieved 90% or
higher coverage for vaccination, achieving high coverage
for screening is always a challenge. A further consider-
ation is disruption to health services as a result of emer-
gencies such as the current COVID-2019 pandemic [61,
62]. Our data should be interpreted in the context of the
challenges and disruptions that may happen in the
health sector from time to time. Third, we did not con-
sider the marginal increase in unit costs as population
coverage increases, due to the difficulty in covering
hard-to-reach populations. Especially if we use GDP per
capita as an alternative threshold to assess the optimal
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strategies, the marginal costs may be more obvious due
to a relatively intensive screening. For example, the strat-
egy of screening every 3 years makes it very difficult and
costly to deliver about 100 million screening services per
year around 2030 (Additional file 2: Figure S11a).
Conclusions
China can achieve the goal of cervical cancer elimination
by the late 2040s (namely, ahead of the second Chinese
Centennial Goals) while saving net economic costs by
adopting the optimal pathway of interventions we
propose from 2021 (namely, the year of the first Chinese
Centennial Goals) onwards. To achieve the goal of elim-
ination, China needs to increase investment for cervical
cancer prevention during 2021–2035 and improve in-
vestment efficiency. Such investment is worthwhile both
from the perspective of health economic evaluation and
public health services, because it will eventually save
China about $100 billion of costs and avoid 7.5 million
cervical cancer cases and 2.5 million cervical cancer
deaths in 2021–2100.
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